Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients

Clinical Pharmacokinetics

Volumn 50, Issue 11, 2011, Pages 739-750

  Van Kralingen, Simone ^a   Diepstraten, Jeroen ^a   Peeters, Mariska Y M ^a   Deneer, Vera H M ^a   Van Ramshorst, Bert ^a   Wiezer, Ren J ^a   Van Dongen, Eric P A ^a   Danhof, Meindert ^b   Knibbe, Catherijne A J ^a,b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Body weight; Dose prediction; Obesity; Overweight; Pharmacodynamic modelling; Pharmacokinetic modelling; Pharmacokinetic pharmacodynamic relationships; Pharmacology; Propofol

Indexed keywords

PROPOFOL;

ADULT; ALLOMETRY; ANESTHESIA; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; COMPUTER PROGRAM; CONCENTRATION (PARAMETERS); DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GASTRIC BANDING; HUMAN; LEAN BODY WEIGHT; MALE; MORBID OBESITY; POPULATION; PRIORITY JOURNAL; STOMACH BYPASS;

ANESTHETICS, INTRAVENOUS; BODY MASS INDEX; BODY WEIGHT; CONSCIOUSNESS MONITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY, MORBID; PROPOFOL;

EID: 80053591387     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11592890-000000000-00000     Document Type: Article

References (36)

1. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006 Apr 5; 295 (13): 1549-55
2. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and causespecific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009 Mar 28; 373 (9669): 1083-96
3. World Health Organization. Obesity: preventing and managing the global epidemic. Geneva: World Health Organization, 1997
4. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000 Sep; 39 (3): 215-31
5. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49 (2): 71-87
6. Servin F, Farinotti R, Haberer JP, et al. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide: a clinical and pharmacokinetic study. Anesthesiology 1993 Apr; 78 (4): 657-65 (Pubitemid 23110039)
7. Schuttler J, Ihmsen H. Population pharmacokinetics of propofol: a multicenter study. Anesthesiology 2000 Mar; 92 (3): 727-38 (Pubitemid 30130176)
8. McLeay SC, Morrish GA, Kirkpatrick CM, et al. Encouraging the move towards predictive population models for the obese using propofol as a motivating example. Pharm Res 2009 Jul; 26 (7): 1626-34
9. Cort́ nez LI, Anderson BJ, Penna A, et al. Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. Br J Anaesth 2010 Oct; 105 (4): 448-56
10. Knibbe CA, Voortman HJ, Aarts LP, et al. Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan-10 after bolus injection. Br J Clin Pharmacol 1999 Jun; 47 (6): 653-60 (Pubitemid 29257663)
11. Knibbe CA, Zuideveld KP, DeJongh J, et al. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. Clin Pharmacol Ther 2002 Dec; 72 (6): 670-84 (Pubitemid 36021006)
12. Van Kralingen S, Diepstraten J, Van de Garde EM, et al. Comparative evaluation of propofol 350 and 200 mg for induction of anaesthesia in morbidly obese patients: a randomized double-blind pilot study. Eur J Anaesthesiol 2010 Jun; 27 (6): 572-4
13. Egan TD, Huizinga B, Gupta SK, et al. Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology 1998 Sep; 89 (3): 562-73 (Pubitemid 28423952)
14. Knibbe CA, Koster VS, Deneer VH, et al. Determination of propofol in lowvolume samples by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 1998 Mar 20; 706 (2): 305-10 (Pubitemid 28130317)
15. Beal SL, Sheiner LB, Boeckmann A. NONMEM user's guide. San Francisco (CA): University of California, 1999
16. StruysMM, Coppens MJ,DeNeve N, et al. Influence of administration rate on propofol plasma-effect site equilibration. Anesthesiology 2007 Sep; 107 (3): 386-96 (Pubitemid 47329536)
17. Pai MP, Paloucek FP. The origin of the "ideal" body weight equations. Ann Pharmacother 2000 Sep; 34 (9): 1066-9 (Pubitemid 30660784)
18. Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44 (10): 1051-65 (Pubitemid 41356391)
19. Van Kralingen S, Van de Garde EMW, Van Dongen EPA, et al. Maintenance of anesthesia in morbidly obese patients using propofol with continuous BISmonitoring: a comparison of propofol-remifentanil and propofol-epidural anesthesia. Acta Anaesthesiol Belg. In press
20. Janmahasatian S, Duffull SB, Chagnac A, et al. Lean body mass normalizes the effect of obesity on renal function. Br J Clin Pharmacol 2008 Jun; 65 (6): 964-5 (Pubitemid 351677429)
21. Han PY, Duffull SB, Kirkpatrick CM, et al. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007 Nov; 82 (5): 505-8 (Pubitemid 47622534)
22. Mathieu P, Lemieux I, Despres JP. Obesity, inflammation, and cardiovascular risk. Clin Pharmacol Ther 2010 Apr; 87 (4): 407-16
23. Lloret Linares C, Decleves X, Oppert JM, et al. Pharmacology of morphine in obese patients: clinical implications. Clin Pharmacokinet 2009; 48 (10): 635-51
24. Bjornsson MA, Norberg A, Kalman S, et al. A two-compartment effect site model describes the bispectral index after different rates of propofol infusion. J Pharmacokinet Pharmacodyn 2010 Jun; 37 (3): 243-55
25. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979 Mar; 25 (3): 358-71 (Pubitemid 9164953)
26. Mandema JW, Veng-Pedersen P, Danhof M. Estimation of amobarbital plasma-effect site equilibration kinetics: relevance of polyexponential conductance functions. J Pharmacokinet Biopharm 1991 Dec; 19 (6): 617-34
27. Visser SA, Smulders CJ, Reijers BP, et al. Mechanism-based pharmacokineticpharmacodynamic modeling of concentration-dependent hysteresis and biphasic electroencephalogram effects of alphaxalone in rats. J Pharmacol Exp Ther 2002 Sep; 302 (3): 1158-67 (Pubitemid 34920239)
28. Wang LP, McLoughlin P, Paech MJ, et al. Low and moderate remifentanil infusion rates do not alter target-controlled infusion propofol concentrations necessary to maintain anesthesia as assessed by bispectral index monitoring. Anesth Analg 2007 Feb; 104 (2): 325-31 (Pubitemid 46146738)
29. Ferreira DA, Nunes CS, Antunes LM, et al. The effect of a remifentanil bolus on the bispectral index of the EEG (BIS) in anaesthetized patients independently from intubation and surgical stimuli. Eur J Anaesthesiol 2006 Apr; 23 (4): 305-10 (Pubitemid 43351134)
30. Bouillon TW, Bruhn J, Radulescu L, et al. Pharmacodynamic interaction between propofol and remifentanil regarding hypnosis, tolerance of laryngoscopy, bispectral index, and electroencephalographic approximate entropy. Anesthesiology 2004 Jun; 100 (6): 1353-72 (Pubitemid 38679303)
31. Liu N, Chazot T, Huybrechts I, et al. The influence of a muscle relaxant bolus on bispectral and datex-ohmeda entropy values during propofol-remifentanil induced loss of consciousness. Anesth Analg 2005 Dec; 101 (6): 1713-8 (Pubitemid 41720626)
32. Bonhomme V, Hans P. Muscle relaxation and depth of anaesthesia: where is the missing link? Br J Anaesth 2007 Oct; 99 (4): 456-60 (Pubitemid 47412486)
33. Marsh B, White M, Morton N, et al. Pharmacokinetic model driven infusion of propofol in children. Br J Anaesth 1991 Jul; 67 (1): 41-8
34. Schnider TW, Minto CF, Gambus PL, et al. The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. Anesthesiology 1998 May; 88 (5): 1170-82 (Pubitemid 28216859)
35. Absalom AR, Mani V, De Smet T, et al. Pharmacokinetic models for propofol: defining and illuminating the devil in the detail. Br J Anaesth 2009 Jul; 103 (1): 26-37
36. La Colla L, Albertin A, La CollaG, et al. No adjustment vs adjustment formula as input weight for propofol target-controlled infusion in morbidly obese patients. Eur J Anaesthesiol 2009 May; 26 (5): 362-9